Clinical Presentation of Hepatocellular Carcinoma in African Americans vs. Caucasians: A Retrospective Analysis

Hrishikesh Samant1, Kapil Kohli1, Krunal Patel2

  • 1Section of Gastroenterology and Hepatology, Departments of Medicine, Ochsner-LSU Health Sciences Center in Shreveport, Shreveport, LA 71103, USA.

Insights

African American patients with hepatocellular carcinoma (HCC) were diagnosed at an older age and had more risk factors than white patients. These findings highlight disparities and inform targeted HCC surveillance programs.

Area of Science:

  • Hepatology
  • Oncology
  • Public Health

Background:

  • Hepatocellular carcinoma (HCC) is a significant cause of cancer mortality globally.
  • Ethnic disparities in HCC survival exist, but contributing factors require further understanding.
  • A tertiary medical center with a majority African American population was studied to explore HCC survival factors.

Purpose of the Study:

  • To investigate the influence of risk factors, including ethnic background, on hepatocellular carcinoma (HCC) survival.
  • To identify demographic, comorbidity, and tumor-related differences in HCC patients across ethnic groups.

Main Methods:

  • Retrospective analysis of 229 HCC patient data from 2008-2018.
  • Inclusion of demographics, comorbidities, liver disease, and tumor characteristics.
  • Statistical analysis using Chi-Square and one-way ANOVA.

Main Results:

  • African American (AA) HCC patients (57.2%) were older at diagnosis compared to non-Hispanic Caucasians (42.7%).
  • AA patients exhibited higher rates of diabetes, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
  • AA patients presented with larger HCC tumors and were more likely to be outside Milan criteria.

Conclusions:

  • AA patients with HCC face unique challenges, including older age at diagnosis and increased metabolic risk factors.
  • Findings suggest a need for tailored HCC surveillance strategies to address ethnic disparities.
  • Understanding these factors is crucial for improving prognostic and diagnostic approaches in HCC care.